A comprehensive view of Gilead Sciences Inc.. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Health Care Sector Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

Gilead completes acquisition of CymaBay Therapeutics for US$4.3B, enhancing its liver disease treatment portfolio with lead product candidate seladelpar for primary biliary cholangitis; CymaBay now a wholly owned subsidiary of Gilead
Published: March 22, 2024 by Business Wire
Gilead and Merus partner to discover novel antibody-based trispecific T-Cell engagers: Gilead will pay US$81.0M upfront for access to Merus' Triclonics platform for cancer treatment research, with potential payments of up to US$1.5B
Published: March 06, 2024 by Business Wire
Gilead to present new data on HIV, COVID-19 and viral hepatitis treatments at the 31st Conference on Retroviruses and Opportunistic Infections; the analyses from nearly 80 studies include research on Biktarvy, Veklury, and Hepcludex
Published: February 26, 2024 by Business Wire
Gilead Sciences to purchase CymaBay Therapeutics for US$4.3B to expand its liver disease portfolio; deal give Gilead access to Seladelpar, a promising drug for the treatment of primary biliary cholangitis slated for potential FDA approval in 2024
Published: February 12, 2024 by Business Wire
Morningstar names Gilead a top dividend stock, noting stellar profit margins with HIV/hepatitis C virus portfolio, which requires small salesforce and inexpensive manufacturing; however, smart future acquisitions among factors needed to return to growth
Published: January 22, 2024 by Victoria Advocate

Ask us about our Health Care Sector market view

Trending Chart

Interactive chart with headline count